Novel HSV-2 Vax Shows Promise

An investigational therapeutic vaccine against type 2 herpes simplex virus, used with an adjuvant, reduced viral shedding in a placebo-controlled trial, a researcher said. The GEN-003 is the first vaccine to reduce the rate of viral shedding from genital herpes, according to Anna Wald, MD, MPH, of the University of Washington in Seattle. http://www.medpagetoday.com/MeetingCoverage/IDWeek/48051?xid=nl_mpt_DHE_2014-10-13&utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=ST&eun=g721819d0r&userid=721819&email=amydugan2%40gmail.com&mu_id=5883165&utm_term=Daily%20B